1227160-16-8

Basic information

• Product Name: 3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzenecarboximide amide
• Synonyms: 3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzenecarboximide amide
• CAS NO: 1227160-16-8
• Molecular Weight: 254.596
• Mol File: 1227160-16-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzenecarboximide amide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzenecarboximide amide(1227160-16-8)
• EPA Substance Registry System: 3-chloro-N'-hydroxy-4-(trifluoromethoxy)benzenecarboximide amide(1227160-16-8)

Safety Data

• Hazardous Substances Data: 1227160-16-8(Hazardous Substances Data)

Upstream product

• 129604-26-8 3-chloro-4-(trifluoromethoxy)benzonitrile 

Relevant articles and documents

PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS

The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.